Immunomedics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:N/A
Industry:Biotech
Founded:1982
Lead Investor(s):Goldman, Sachs & Co.
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • Immunomedics's revenue is currently $34.6M per year.
  • Immunomedics received $125.0M in venture funding in May 2017.
  • Immunomedics's revenue per employee is $97366

Employee Data

  • Immunomedics has 355 Employees.
  • Immunomedics grew their employee count by 59% last year.
  • Immunomedics currently has 22 job openings.

What Is Immunomedics?

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates.

keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power

355

Number of Employees

$34.6M

Revenue (est)

22

Current Jobs

59%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
GENEWIZ
$75.8M5196%
Hitachi Chemica...
$29.9M22919%
GENEWIZ
$75.8M5196%
Hitachi Chemica...
$29.9M22919%
Canfield Scient...
$29.3M2048%
Thomas Scientif...
$21.5M16720%
Canfield Scient...
$29.3M2048%
Thomas Scientif...
$21.5M16720%
L Oreal USA
N/A5227%
L Oreal USA
N/A5227%

Immunomedics News

20-Mar-19 - SG Americas Securities LLC Acquires New Holdings in

SG Americas Securities LLC bought a new position in Immunomedics, Inc. (NASDAQ:IMMU) during the 4th quarter, according to its most recent

59 minutes ago - Why Investors remain confident on Immunomedics, Inc. (IMMU

Immunomedics, Inc. (NASDAQ: IMMU) experienced a high price of $18.59 with a low value of $17.8 at the end of the last trading session, which

25-Feb-19 - Immunomedics, Inc. (IMMU) on Q2 2019 Results - Earnings Call

Immunomedics, Inc. (NASDAQ:IMMU) Q2 2019 Earnings Conference Call February 25, 2019 5:00 PM ET. Company Participants. Chau Cheng

Immunomedics Funding

DateAmountRoundLead InvestorsReference
2004-01-15$10.0MnotesArticle
2005-04-28$36.7MUndisclosedMultipleArticle
2014-05-05$30.2MUndisclosedArticle
2015-02-09$96.4MUndisclosedGoldman, Sachs & Co.Article
2017-05-08$125.0MUndisclosedArticle

Immunomedics Executive Hires

DateNameTitleReference
2001-09-12Gerald GormanCFOArticle
2002-03-26Terence RuggCMO & SVPArticle
2002-05-03Ivan HorakEVP Research & DevelopmentArticle
2013-09-04Peter PfreundschuhCFO/VP FinanceArticle
2015-01-07Francois E. WilhelmChief Medical OfficerArticle
2016-06-22Michael R. GaroneVP Finance/CFOArticle
2017-05-08Michael GaroneInterim CEOArticle
2019-02-27Scott Canuteexecutive directorArticle